A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms TOUCHSTONE
  • Sponsors Celgene Corporation; Celgene International SARL; Receptos
  • Most Recent Events

    • 03 Aug 2018 Results published in the Gut.
    • 01 Nov 2017 Results of an open-label extension of this trial (n=170, data cut-off:Mar 2017, 2 year follow up) assessing the long-term efficacy and safety of daily 1 mg ozanimod, presented at the 25th United European Gastroenterology Week.
    • 16 Oct 2017 According to a Celgene Corporation media release, data from the open-label extension will be presented at the World Congress of Gastroenterology at ACG2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top